CS acquires AxeroVision’s dry eye disease pipeline
Drug Discovery World
JULY 31, 2023
CS Pharmaceuticals (CSP) has acquired AxeroVision, a company developing novel therapies for the treatment of dry eye disease (DED) and other ophthalmic inflammatory diseases that address the underlying inflammatory processes.
Let's personalize your content